<DOC>
	<DOCNO>NCT02404675</DOCNO>
	<brief_summary>This randomize , open-label study aim evaluate efficacy high-dose icotinib treat advance non-small cell lung cancer patient positive EGFR 21 exon mutation .</brief_summary>
	<brief_title>High Dose Icotinib Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB/IV lung cancer ( exclude patient confirm sputum cytology ) Positive EGFR 21 exon mutation 19 exon deletion Age 1875 year old performance status 0 2 With measurable disease ( long diameter &gt; =10mm Spiral compute tomography ( CT ) &gt; =20mm conventional CT ) accord RECIST Criteria Adequate hematological , biochemical organ function . Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease . Evidence interstitial lung disease Evidence significant clinical disorder laboratory find make undesirable subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>